Karlsson M, Korkolainen T, Wikberg T
Orion Corporation, Orion Pharma, Espoo, Finland.
Biomed Chromatogr. 1997 Jan-Feb;11(1):54-8. doi: 10.1002/(SICI)1099-0801(199701)11:1<54::AID-BMC629>3.0.CO;2-L.
A fully automated method for quantitation of levosimendan, (R)-(-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl]hydrazono]propanedinitrile, in human plasma is described. The method involves on-line dialysis of the samples, trace enrichment of the dialysates, and reversed-phase high-performance liquid chromatography with UV detection at 380 nm. An internal standard was used to compensate for variations in the dialysis rate caused by temperature fluctuations. The precision and accuracy of the method were good. The between-day variation (RSD) was 2.7% at a plasma concentration of 15 ng/mL and 1.7% at 450 ng/mL. The limit of quantitation was 5 ng/mL with an RSD of 4.0%. The completion time of the assay was 19 min.
本文描述了一种用于定量测定人血浆中左西孟旦（(R)-(-)-[[4-(1,4,5,6-四氢-4-甲基-6-氧代-3-哒嗪基)苯基]腙]丙二腈）的全自动方法。该方法包括样品的在线透析、透析液的痕量富集以及在380nm处进行紫外检测的反相高效液相色谱法。使用内标来补偿温度波动引起的透析速率变化。该方法的精密度和准确度良好。在血浆浓度为15 ng/mL时，日间变化（相对标准偏差）为2.7%，在450 ng/mL时为1.7%。定量限为5 ng/mL，相对标准偏差为4.0%。测定完成时间为19分钟。
